Last updated: February 19, 2026
This report analyzes key considerations for biopharmaceutical patent filings at the African Intellectual Property Organization (OAPI). It details patentability requirements, enforceability mechanisms, and common claim scope limitations relevant to drug discovery and development.
What Are the Core Patentability Requirements for Biopharmaceuticals in OAPI?
OAPI patentability adheres to the Bangui Agreement, which establishes common rules for intellectual property in its member states. For biopharmaceutical inventions, the core requirements include novelty, inventive step, and industrial applicability.
Novelty
An invention is considered novel if it has not been disclosed to the public anywhere in the world before the filing date of the patent application. Disclosure can occur through publications, public use, sale, or any other means. For biopharmaceuticals, this means demonstrating that the claimed compound, method, or use is not previously known.
- Prior Art Search: A thorough prior art search is critical to establish novelty. This includes searching existing patent databases, scientific literature, and public disclosures.
- Enablement: The patent application must describe the invention in sufficient detail to enable a person skilled in the art to carry it out. This is particularly relevant for biological entities where specific methods of isolation, characterization, and production are essential.
Inventive Step
An invention involves an inventive step if, having regard to the state of the art, it is not obvious to a person skilled in the art. This requires demonstrating that the biopharmaceutical innovation is more than a mere trivial variation of existing knowledge.
- Non-Obviousness: For a new drug compound, demonstrating non-obviousness might involve showing unexpected efficacy, a superior pharmacokinetic profile, or a novel mechanism of action compared to known therapeutic agents.
- Technical Effect: The claimed invention must produce a technical effect. For instance, a new formulation of an existing drug could be patentable if it demonstrates improved bioavailability, reduced side effects, or enhanced stability.
Industrial Applicability
The invention must be capable of being made or used in any kind of industry, including agriculture. For biopharmaceuticals, this generally means the drug or therapeutic process has a practical application in medicine or healthcare.
- Therapeutic Use: A novel compound that can be used to treat a disease is industrially applicable. Methods of treatment, diagnostic methods related to specific diseases, and pharmaceutical compositions containing the active ingredient also meet this criterion.
- Manufacturing Process: Processes for producing biological molecules, such as recombinant proteins or antibodies, are also considered industrially applicable.
What Are the Specific Provisions for Patenting Biological Materials and Methods?
OAPI patent law has specific considerations regarding the patenting of biological materials and related methods.
Patentable Subject Matter
While general inventions are patentable, OAPI law, like many jurisdictions, excludes certain subject matter.
- Discoveries vs. Inventions: Discoveries of naturally occurring substances are generally not patentable. However, an isolated and purified form of a naturally occurring substance, or a novel use of such a substance, can be patentable if it meets the criteria for novelty and inventive step.
- Human Body: Inventions concerning the human body at the various stages of its formation and development, and the mere discovery of one of its elements, including the sequence or partial sequence of a gene, are not patentable. However, a product consisting of or comprising a gene sequence or a partial gene sequence may be patentable if it is isolated from its natural environment and if the function of the sequence or partial sequence is disclosed and has an industrial application.
Plant Varieties and Animal Breeds
The Bangui Agreement explicitly excludes plant varieties and animal breeds from patent protection. However, inventors may be able to patent specific genetically modified organisms (GMOs) or methods for their production if they do not fall under the exclusion for plant varieties or animal breeds.
Microorganisms
Microorganisms, provided they are not naturally occurring and are produced by means of a microbiological process and are capable of self-reproduction or reproduction in a viable form, are generally patentable.
Methods of Medical Treatment
Methods of treatment of the human or animal body by surgery or therapy, and diagnostic methods practiced on the human or animal body, are not patentable. However, this exclusion does not apply to products, in particular apparatus or instruments, for use in any of these methods.
- First Medical Use: The OAPI patent system, through interpretation and practice, generally recognizes the patentability of new medical uses for known compounds. This is crucial for repurposing existing drugs. A claim directed to a new therapeutic indication of a known substance can be patentable if the substance is novel for that indication and the indication itself offers a technical advantage.
How Are Claims Scoping Biopharmaceutical Inventions Typically Drafted and Interpreted in OAPI?
The scope of patent claims is critical for defining the extent of exclusive rights granted. OAPI claim drafting follows principles similar to those in major patent jurisdictions, with an emphasis on clarity and support by the specification.
Types of Claims
Common claim types for biopharmaceuticals include:
- Product Claims: Claims directed to a specific compound (e.g., a small molecule, antibody, protein), a pharmaceutical composition containing the compound, or a diagnostic kit.
- Process Claims: Claims covering methods of manufacturing a biopharmaceutical product, methods of isolating a biological material, or methods of gene sequencing.
- Use Claims: Claims directed to the use of a compound or composition for a specific therapeutic purpose. This is particularly important for first medical use patents.
- Method of Treatment Claims: As noted, these are generally not patentable. However, claims directed to "product for use in treating X" are permissible.
Claim Interpretation Principles
OAPI claims are interpreted based on the language of the claims themselves, read in light of the description and drawings of the patent application.
- Literal Interpretation: Claims are given their plain meaning.
- Doctrine of Equivalents: While not as extensively codified or consistently applied as in some other jurisdictions, the principle of equivalents can be invoked to cover variations that perform substantially the same function in substantially the same way to achieve substantially the same result, provided such equivalents were not obvious to a person skilled in the art at the time of filing.
- Support in Description: Claims must be fully supported by the detailed description. Broad claims must be justified by a broad disclosure. For biological inventions, this means providing sufficient experimental data and detailed methodologies.
Claim Scope Limitations
Several factors can limit the scope of biopharmaceutical claims:
- Prior Art: Claims are limited by the scope of the prior art. Anything disclosed or rendered obvious by the prior art will not be covered.
- Enablement: If the description does not enable a person skilled in the art to carry out the claimed invention across its full scope, the scope may be limited. For example, claiming a genus of compounds without providing adequate examples or structural parameters might lead to a restricted scope.
- Clarity and Definiteness: Claims must be clear and definite. Ambiguous or indefinite claims can be narrowed or found invalid.
- Disclosure of Functional Properties: Claims based on the function of a biological entity (e.g., a protein with a specific enzymatic activity) require a clear definition of that function and evidence to support it.
What Are the Enforcement Mechanisms for Biopharmaceutical Patents in OAPI?
Enforcement of patent rights in OAPI member states relies on national patent laws, as OAPI itself does not have a unified enforcement body.
National Enforcement Procedures
Upon grant by OAPI, patents are validated in designated member states, which then become legally enforceable under national law.
- Infringement Actions: Patent holders can initiate infringement lawsuits in the national courts of the OAPI member states where their patent is in force.
- Remedies: Remedies for infringement typically include:
- Injunctions: Court orders to cease infringing activities.
- Damages: Monetary compensation for losses incurred due to infringement.
- Seizure of Infringing Goods: Order for the seizure of counterfeit or infringing products.
- Burden of Proof: The patent holder typically bears the burden of proving infringement. However, in cases involving a product obtained directly by means of a patented process, the burden may shift to the alleged infringer to prove that the process used is different from the patented one. This is particularly relevant for process patents in the pharmaceutical industry.
Role of National Patent Offices and Courts
- National Patent Offices: While OAPI handles the grant, national patent offices of member states may be involved in post-grant procedures such as oppositions or cancellations, depending on the specific national laws.
- National Courts: The judiciary of each member state is responsible for interpreting and enforcing patents. The quality and consistency of judicial interpretation can vary across member states.
Challenges in Enforcement
- Divergent National Laws: Although OAPI provides a unified application and grant process, national laws regarding enforcement, remedies, and procedural aspects can differ, leading to complexities.
- Cost and Time: Patent litigation can be expensive and time-consuming in any jurisdiction, and OAPI member states are no exception.
- Proof of Infringement: For process patents, demonstrating infringement can be challenging, especially when the manufacturing process is a trade secret.
What Are the Key Considerations for Filing Biopharmaceutical Patents in OAPI?
Strategic planning is essential for maximizing the value of biopharmaceutical patents within the OAPI framework.
Prior Art and Novelty Assessment
- Comprehensive Search: Conduct a rigorous prior art search that encompasses global patent databases, scientific literature, and any public disclosures relevant to the biopharmaceutical invention.
- Early Disclosure Awareness: Be aware of any potential prior disclosures by the applicant or third parties, as these can impact novelty.
Inventive Step Demonstration
- Unexpected Results: Clearly articulate and provide data demonstrating unexpected advantages or technical effects compared to the closest prior art. This could include improved efficacy, reduced toxicity, novel mechanisms of action, or superior pharmacokinetic properties.
- Problem-Solution Approach: Frame the invention as solving a specific technical problem that was not readily solvable by the prior art.
Disclosure and Enablement
- Detailed Description: Provide a complete and detailed description of the invention, including all necessary information for a skilled person to reproduce it. For biological inventions, this means providing sequence information, methods of isolation, characterization data, and manufacturing protocols.
- Working Examples: Include sufficient working examples to support the breadth of the claims. This is especially critical for claiming large chemical or biological families.
Claim Drafting Strategy
- Broad vs. Narrow Claims: Draft a set of claims that includes both broad claims (e.g., genus claims for compounds or antibodies) and narrower, dependent claims that provide fallback positions.
- Medical Use Claims: Utilize first and further medical use claims where applicable, ensuring they are clearly drafted to be patentable under OAPI practice.
- Product-by-Process Claims: Consider product-by-process claims if the product itself is not novel but is produced by a novel process, and ensure the product is defined by its characteristics and not solely by the process.
Post-Grant Strategy
- Validation Strategy: Carefully select the OAPI member states for validation based on market size, strategic importance, and enforcement landscape.
- Freedom-to-Operate (FTO) Analysis: Conduct FTO analyses to assess the risk of infringing existing patents in target markets.
- Monitoring and Enforcement: Establish a robust system for monitoring the market for potential infringements and be prepared to enforce patent rights through national courts.
Collaboration with Local Counsel
- Expertise: Engage with experienced patent attorneys or agents in OAPI member states who have a deep understanding of local patent laws and judicial practices.
- Validation and Prosecution: Local counsel is essential for managing the validation process, responding to any national office actions, and handling enforcement matters.
Key Takeaways
- OAPI patentability for biopharmaceuticals hinges on novelty, inventive step, and industrial applicability, with specific exclusions for naturally occurring discoveries and methods of medical treatment.
- Patentable subject matter includes isolated biological materials, microorganisms produced by technical processes, and new medical uses of known compounds.
- Claim scope is determined by literal interpretation, supported by the specification, and is limited by prior art, enablement requirements, and clarity.
- Enforcement of OAPI patents occurs at the national level within member states, with remedies including injunctions and damages.
- Strategic patent filing, robust disclosure, careful claim drafting, and a targeted validation strategy are critical for protecting biopharmaceutical innovations in OAPI member states.
Frequently Asked Questions
- Can a gene sequence identified in a human be patented in OAPI?
A gene sequence itself, as a mere discovery of an element of the human body, is not patentable. However, if the gene sequence is isolated from its natural environment and its function is disclosed and has an industrial application, it may be patentable.
- Are diagnostic methods performed on the human body patentable under OAPI?
No, diagnostic methods practiced on the human or animal body are not patentable. However, products such as diagnostic kits or instruments used in these methods can be patented.
- What is the impact of the Bangui Agreement on biopharmaceutical patenting in OAPI?
The Bangui Agreement establishes the common framework for intellectual property within OAPI, harmonizing patentability criteria, including novelty, inventive step, and industrial applicability, across member states for inventions like biopharmaceuticals.
- How is the "inventive step" requirement assessed for a new formulation of an existing drug?
An inventive step for a new formulation is assessed by demonstrating that it provides a non-obvious improvement over existing formulations, such as enhanced stability, improved bioavailability, reduced side effects, or a novel delivery mechanism, leading to a technical advantage.
- Can a patent granted by OAPI be enforced in all member states simultaneously?
A patent granted by OAPI must be validated in individual member states to be enforceable within their respective national territories. Enforcement is then pursued through the national judicial systems of those validated states.
Citations
[1] African Intellectual Property Organization. (n.d.). The Bangui Agreement Relating to the Creation of an Industrial Property Office for Africa and Relating to its Establishment. Retrieved from [relevant OAPI treaty source, if publicly accessible online, otherwise refer to official treaty documents].
